^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    HLF overexpression + FLT3-ITD mutation

    i
    Other names: HLF, HLF Transcription Factor, PAR BZIP Family Member, Hepatic Leukemia Factor, HLF PAR BZIP Transcription Factor, PAR BZIP Transcription Factor, MGC33822, E2A-HLF Fusion Transcript Protein, FLT3, Fms Related Tyrosine Kinase 3, Receptor-Type Tyrosine-Protein Kinase FLT3, Stem Cell Tyrosine Kinase 1, Fms-Like Tyrosine Kinase 3, CD135, FLK-2, STK1, Growth Factor Receptor Tyrosine Kinase Type III, Fetal Liver Kinase 2
    Entrez ID:
    2322; 3131
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    over2years
    FLT3-ITD allelic ratio and HLF expression predict FLT3 inhibitor efficacy in adult AML. (PubMed, Sci Rep)
    The retrospective analysis of AML patients treated with FLT3 inhibitor sorafenib showed that patients with high HLF expression and ITD-AR had better clinical response to therapy compared to those with low ITD-AR and HLF expression. Thus, our findings suggest that FLT3 ITD-AR together with increased HLF expression play a role in variable FLT3 inhibitor responses observed in FLT3-ITD AML patients.
    Clinical • Retrospective data • Journal
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3-ITD mutation • FLT3 expression • FLT3-ITD expression • HLF overexpression + FLT3-ITD mutation
    |
    sorafenib